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Epidemiological studies consistently show that circulating sex hormone binding globulin (SHBG) levels are
lower in type 2 diabetes patients than non-diabetic individuals, but the causal nature of this association is
controversial. Genetic studies can help dissect causal directions of epidemiological associations because
genotypes are much less likely to be confounded, biased or influenced by disease processes. Using this
Mendelian randomization principle, we selected a common single nucleotide polymorphism (SNP) near the
SHBG gene, rs1799941, that is strongly associated with SHBG levels. We used data from this SNP, or closely
correlated SNPs, in 27 657 type 2 diabetes patients and 58 481 controls from 15 studies. We then used data
from additional studies to estimate the difference in SHBG levels between type 2 diabetes patients and con-
trols. The SHBG SNP rs1799941 was associated with type 2 diabetes [odds ratio (OR) 0.94, 95% CI: 0.91, 0.97;
P 5 2 3 1025], with the SHBG raising allele associated with reduced risk of type 2 diabetes. This effect was
very similar to that expected (OR 0.92, 95% CI: 0.88, 0.96), given the SHBG-SNP versus SHBG levels associ-
ation (SHBG levels are 0.2 standard deviations higher per copy of the A allele) and the SHBG levels versus
type 2 diabetes association (SHBG levels are 0.23 standard deviations lower in type 2 diabetic patients com-
pared to controls). Results were very similar in men and women. There was no evidence that this variant is
associated with diabetes-related intermediate traits, including several measures of insulin secretion and
resistance. Our results, together with those from another recent genetic study, strengthen evidence that
SHBG and sex hormones are involved in the aetiology of type 2 diabetes.
INTRODUCTION
Circulating sex hormone levels are associated with type 2 dia-
betes, but the causal nature of these associations is controver-
sial. Many observational epidemiological studies have
described associations between type 2 diabetes and androgens
(primarily testosterone), estrogens (estradiol) and their circu-
lating binding protein, sex hormone binding protein (SHBG)
(1). Meta-analyses of these studies show consistent
sex-specific associations. In men, lower testosterone, higher
estradiol and lower SHBG levels are associated with type 2
diabetes. In women, higher testosterone, higher estradiol and
lower SHBG are associated with type 2 diabetes (1).
The differences in sex hormone levels between type 2 dia-
betes patients and controls are complicated by increased
adiposity, which is also associated with reduced SHBG.
However, differences in adiposity cannot fully explain the
associations between sex hormones and type 2 diabetes. In
both men and women, the differences in testosterone, estradiol
and SHBG levels between type 2 diabetes patients and non-
diabetic individuals remain very similar before and after con-
trolling for BMI, age, ethnic background and, in females,
menopausal status (1).
There is evidence that the associations between sex hormones
and type 2 diabetes may be causal. First, a recent study
described an association between two SNPs in the SHBG
gene and type 2 diabetes (2). Second, prospective studies
show that the levels of sex hormones are altered in individuals
diagnosed many years later (1). Third, hyper-androgenic dis-
orders such as polycystic ovarian syndrome (PCOS) in
women result in an increased risk of type 2 diabetes and are
very strongly associated with insulin resistance (3). In men,
androgen supplementation in the presence of central obesity
and low testosterone levels increases insulin sensitivity (4–6).
Fourth, male rats lacking the androgen receptor are insulin
resistant (7) and female rats treated with testosterone after
oophorectomy become insulin resistant (8), findings that are
consistent with the sex-specific associations seen in humans.
Despite some evidence pointing towards a causal role of sex
hormones in type 2 diabetes, further evidence is required. The
recent genetic study involved a relatively small number of
patients (359 women and 170 men), the effect sizes, with
odds ratios (ORs) of 1.52 and 1.39, are similar to those for
SNPs in the TCF7L2 gene (9), which raises doubt as to why
these associations were not found by genome-wide association
approaches, and the evidence of association between SHBG
SNPs and type 2 diabetes was not strong (P ¼ 0.02 for each
SNP under the best model) (2). It is well known that even
well-conducted, well-controlled epidemiological associations
can often be confounded by imperfect measurement of
known, or unknown, related factors. Prospective studies estab-
lish whether or not a risk factor is present prior to disease diag-
nosis, but do not necessarily solve the concerns about
epidemiological studies. Disease processes can start many
years before disease diagnosis, which means that altered
hormone levels observed prospectively could be a
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consequence rather than cause of early disease processes. The
causal direction of the associations between hyper-androgenism
and insulin resistance in PCOS is not known. Studies in animals
may not be relevant to humans and human trials of androgen
therapy have focused on people with extreme levels of
obesity or circulating hormones and conflicting results have
been reported (10,11). Finally, insulin lowering interventions
in non-diabetic men and women (without PCOS) lead to
increased SHBG levels, suggesting that insulin can causally
influence sex hormone dynamics (12,13).
Genetic studies can be a valuable additional tool which help
to dissect causal directions of epidemiological associations
(14). In most situations, alleles at genetic variants are ran-
domly distributed between individuals who differ by conven-
tional confounding factors. This ‘Mendelian randomization’
principle has been used recently in the context of metabolic
traits to provide evidence that lifelong exposure to slightly
raised C-reactive protein (CRP) (15), Interleukin-18 (IL18)
(16), regulated on activation, normal T-cell expressed and
secreted protein (RANTES) (17) or beta-carotene (18) levels
are unlikely to alter the risk of type 2 diabetes, whereas
some evidence for an aetiological association has been
suggested for macrophage migration inhibitory factor (MIF)
(19). Other examples of this approach provide mechanistic
insight to disease. For example the association between vari-
ation in the FTO gene, that is associated with adiposity, and
some cancers, provides some evidence that adiposity has an
aetiological role in cancer (20).
In this study, we used the principle of Mendelian Ran-
domization to provide evidence for or against an aetiological
role of raised SHBG levels and reduced risk of type 2 diabetes.
Our results indicate that higher SHBG levels may reduce the
risk of type 2 diabetes.
RESULTS
Observed association between SHBG SNP and type 2
diabetes risk
We observed evidence of association between the SHBG SNP
rs1799941 and type 2 diabetes (OR 0.94, 95% CI: 0.91, 0.97;
P ¼ 2  1025), with the SHBG raising allele associated with
reduced risk of type 2 diabetes (Figs 1 and 2). This result
included correction for age, sex and BMI across 14 of the
15 studies (one study is uncorrected), but the result was
similar when correcting for age and sex only (OR 0.94, 95%
CI: 0.91, 0.97; P ¼ 2  1025). The result was also similar in
men (OR 0.95, 95% CI: 0.91, 0.99; P ¼ 0.009); and women
(OR 0.93, 95% CI: 0.89, 0.98; P ¼ 0.003). There was no evi-
dence of heterogeneity in any analysis, either between or
within sexes or with and without correction for BMI (all het-
erogeneity P. 0.15, maximum I2—a measure of the variation
in effect size attributable to heterogeneity—29%). There was a
trend towards an increased effect in carriers of two copies of
the SHBG raising allele, compared with carriers of two
copies of the SHBG lowering allele (OR 0.91, 95% CI:
0.85, 0.97; P ¼ 0.006) (uncorrected). The SHBG lowering
(G) allele at rs1799941 ranged in allele frequency from 0.72
to 0.75 in individual study controls and from 0.73 to 0.77 in
individual study type 2 diabetes patients.
Observed differences in SHBG levels between type 2
diabetes patients and controls
Details of the differences in SHBG levels between type 2 dia-
betes patients and controls are given in Table 2 and in
Figures 1 and 3. SHBG levels were 0.233 (95% CI: 20.35,
20.115) standard deviations lower in type 2 diabetes patients
compared with controls, when controlling for BMI. This esti-
mate differed little between men (OR 20.218, 95% CI:
20.360, 20.076) and women (OR 20.264, 95% CI:
20.475, 20.054).
Approximate expected association between SHBG SNP and
type 2 diabetes risk
We next tested whether or not the observed association
between the SHBG SNP and type 2 diabetes was consistent
with that expected if SHBG levels alter the risk of type 2 dia-
betes. We used the estimates of the effect of rs1799941 on cir-
culating SHBG levels and the difference in SHBG levels
between type 2 diabetes patients and controls to calculate an
approximate expected effect of rs1799941 with type 2 diabetes
(Fig. 1). The expected associations were: for men and women
combined (OR 0.92, 95% CI: 0.88, 0.96); for men (OR 0.92,
95% CI: 0.88, 0.97); and for women (OR 0.91, 95% CI:
0.84, 0.98). These estimates were similar to those observed.
Associations between SHBG SNPs and type 2 diabetes
related intermediate traits
We did not detect any association between the SHBG SNP
rs1799941 (or its close proxy rs12150660) and any measures
of intermediate type 2 diabetes related traits in population-
based studies. These included fasting insulin (P ¼ 0.11, N ¼
37 864), the HOMAIR measure of insulin resistance (P ¼
0.24, N ¼ 36 601), fasting glucose (P ¼ 0.52, N ¼ 45 691),
the HOMAB measure of beta-cell function (P ¼ 0.04, N ¼
36,135) [all rs12150660], insulin secretion as assessed by
oral glucose tolerance test-based measures of glucose,
insulin and C-peptide at 30 and 120 min ( all P . 0.14, N ¼
5771) or insulin resistance as measured by hyperinsulinaemic-
euglycaemic clamps (P ¼ 0.94, N ¼ 1229) [all rs1799941].
DISCUSSION
Our study provides evidence that raised circulating SHBG
levels reduce the risk of type 2 diabetes. Our results, together
with those from the recent study by Ding et al. (2), provide
insight into the role of sex hormones in the aetiology of type
2 diabetes. It has been known for some time that circulating
SHBG levels are lower in people with type 2 diabetes com-
pared with non-diabetic individuals, both in cross-sectional
comparisons and prospectively. Despite this association,
there has been considerable doubt as to the causal relevance
of sex hormones in type 2 diabetes. The two genetic studies
therefore add considerably to the argument that sex hormones
are involved in the aetiology of the disease. This may have
important implications for the treatment of diabetes or hypo-
and hyper-androgenism in the two sexes.
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There are several strengths to our study. First, genotypes are
randomly distributed in ethnically homogenous populations,
meaning our results are very unlikely to be confounded or
biased or secondary to diabetes disease processes. Second,
the statistical confidence of the association between the
SHBG variant and type 2 diabetes is very strong—of approxi-
mately 1 million independent common variants in European
genomes, we would only expect 20 to reach this level of
Figure 1. Triangulation approach to assess how the observed association of the SHBG SNP rs1799941 with type 2 diabetes compares with that expected given
the association between rs1799941 and circulating SHBG levels and the difference in SHBG levels between type 2 diabetes patients and controls.
Figure 2. Meta-analysis of rs1799941 in type 2 diabetes case–control studies correcting for or matching for BMI, age and sex. OR, odds ratio.
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statistical confidence by chance. Our results are consistent
across 15 studies comprising 27 657 type 2 diabetic patients
and 58 481 controls, with all but two studies showing an OR
in the expected direction. Third, the ORs we observe
between the SHBG rs1799941 SNP and type 2 diabetes are
consistent with those expected from a triangulation approach.
Fourth, the use of a SNP at the SHBG gene locus strongly
associated with circulating SHBG levels means the association
is very unlikely to be due to a pleiotropic effect of the variant
on another pathway.
There are a few limitations to our study. Most notably we
have not found any evidence for the mechanism behind the
association between SHBG levels and type 2 diabetes.
Despite the large numbers available, we did not observe any
associations with various measures of insulin resistance or
insulin secretion. This lack of association with intermediate
type 2 diabetes traits is not inconsistent with the association
with type 2 diabetes. The OR of 0.94 (equivalent to 1.06 for
the SHBG lowering allele) is small and previous studies of
variants of this magnitude have often not identified any associ-
ations with measures of insulin resistance or insulin secretion
(21). This may in part be due to the reproducibility of
measures based on insulin, which has a very short half life
and fluctuates appreciably within individuals. We note,
however, that the small effect size does not mean the finding
has any less relevance to the question of aetiology, which
relies only on the statistical confidence of the findings.
A further caveat to our study is that we used a different and
much smaller set of patients and controls to estimate the mag-
nitude of the association between circulating SHBG levels and
type 2 diabetes compared with the association between the
SHBG SNP and type 2 diabetes. This difference meant that
the estimated effect is very approximate and may be biased
by the availability of data from previous publications. The
confidence intervals of our estimated effect do not take into
account the error in the estimate of the SNP-SHBG levels
and so this adds further to the uncertainty of this calculation.
Despite these concerns, the estimated and observed ORs for
the SHBG SNP effect on type 2 diabetes were very similar.
There are some notable differences between our study and
that of Ding et al. (2). While both studies support an associ-
ation between SHBG SNPs and type 2 diabetes, the effect
sizes are very different. Ding et al. report ORs of 1.52 (0.66
inverted) and 1.39 for rs6259 and rs6257, respectively.
These ORs are similar to those for SNPs in the TCF7L2
gene, which represent the most strongly associated SNPs in
genome wide association studies of type 2 diabetes. There is
no evidence of association between rs6259 (a non-
synonymous SNP, D356N) and type 2 diabetes in data from
4549 cases and 5579 controls [P¼0.72, OR 1.02 [0.92–
1.12], all of European ancestry] (22), and this SNP appears
to be less strongly associated with SHBG levels than
rs1799941, based on data from previous studies (23,24). The
other SNP reported by Ding et al., rs6257, is not in HapMap
Figure 3. Details of the correlations between SHBG levels and type 2 diabetes from seven cross-sectional studies of European individuals correcting or matching
for BMI or waist circumference.
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but previously published data (25) indicates that rs1799941
and rs6257 are partially correlated and that rs1799941 drives
the association with SHBG levels. These observations,
together with our much larger sample size, suggest that the
small OR of 0.94 is a closer reflection of the true effect size
than that reported by Ding et al.
How might genetically lowered SHBG levels increase the
risk of type 2 diabetes? Previous studies suggest that
rs1799941 has different effects on total testosterone levels in
men and women. Dunning et al. showed that the SHBG low-
ering allele at rs1799941 is not associated with total testoster-
one levels in postmenopausal women (N ¼ 1975) (23). This
means that women with genetically lower SHBG levels are
exposed to proportionally more of the adverse effects of the
biologically active unbound testosterone. In contrast, higher
testosterone levels are thought to protect against adverse meta-
bolic effects in men and Ahn et al. (25) showed that the SHBG
raising allele at rs1799941 is strongly associated with higher
total testosterone levels in men (N ¼ 4678). This explanation
is complicated by the fact that free testosterone levels are
maintained in men by a strong feedback loop whereby lutei-
nizing hormone (LH) production from the pituitary gland in
the presence of low androgen levels stimulates testosterone
production in the testes. This should mean that genetically
lower SHBG levels will not greatly affect free testosterone
levels in men. However, there is recent evidence that bound
testosterone may be biologically active (26). If this is the
case, then men with lower total testosterone due to lower
SHBG will be exposed to less of the protective metabolic
effects of androgens, despite similar levels of unbound
testosterone.
There are additional implications of our results that require
further study. First, our results and those of Ding et al. are not
altered by adjustment or matching for BMI despite the fact
that increased BMI and adiposity are correlated with
reduced SHBG levels. This could mean that altered SHBG
levels are part of the reason why increased BMI causally
increases the risk of type 2 diabetes. Second, a SNP
(rs6259) in the SHBG gene has been associated with prostate
cancer and there is increasing evidence that there may be a
casual link to the inverse association between prostate
cancer and type 2 diabetes (27), although our results suggest
that this requires additional studies of rs1799941 in prostate
cancer (28).
In conclusion, a large type 2 diabetes case–control study
provides strong statistical support for a role of SHBG and
sex hormones in the aetiology of type 2 diabetes.
MATERIALS AND METHODS
Our methods were based on the triangulation approach out-
lined in Figure 1. In summary we used (i) a common single
nucleotide polymorphism (SNP) near the SHBG gene,
rs1799941, previously shown to be very strongly associated
with SHBG levels; (ii) 27 657 type 2 diabetes patients and
58 481 controls from 15 studies to test the association
between this SNP and type 2 diabetes risk; (iii) data from
six studies to estimate the magnitude of the association
between SHBG levels and type 2 diabetes and (iv) existing
data to calculate an approximate expected effect of the
SHBG SNP on type 2 diabetes given the magnitude of the
SNP versus SHBG levels association and the magnitude of
the SHBG levels versus type 2 diabetes association.
Selection of a SNP strongly associated with SHBG levels
Several genetic studies have established unequivocal evidence
that common variation close to the SHBG gene influences cir-
culating SHBG levels. We used previously published infor-
mation to quantify the association between a SNP,
rs1799941, 67 base pairs upstream of the SHBG gene and cir-
culating SHBG levels. Several studies have shown consistent
associations between rs1799941 and SHBG levels (P , 1 
10216) (23–25). Each copy of the A allele is associated with
a 0.20 SDs increase in SHBG levels, based on Finnish
(NFBC66) and Italian (InCHIANTI) population-based
studies, with similar effect sizes in men and women (24).
Observed association between SHBG SNP and type 2
diabetes risk
Through collaboration between 15 studies, we assembled a set
of 27 657 cases and 58 481 controls. These studies varied in
characteristics and ascertainment criteria and details are
given in Table 1. All patients and controls were of European
ancestry. The SHBG SNP rs1799941 was directly genotyped
in all but three studies, two of which used a strongly correlated
SNP (rs12150660 r2 ¼ 0.9 with rs1799941), available as part
of genome wide association data (FUSION1 and DGI), and
a third used a mixture of directly genotyped and imputed
data (Decode). Genotyping methods and quality control
steps are given in Supplementary Material, Table S1. Individ-
ual studies calculated a per allele OR for the A allele at
rs1799941, correcting for age, sex and BMI (except publicly
available DGI data where cases and controls were matched
for gender and BMI, and WTCCC samples, where data for
BMI in controls was not available). The FUSION2 study
additionally corrected for birth province and used 5 year age
category instead of age. We next used the ‘metan’ command
in STATAv10 to meta-analyse these results across all 15
studies. This function weighs all studies by the inverse of
their variance (a function of SNP frequency and study size)
to obtain a per allele estimate of the type 2 diabetes OR for
all studies. We quote the OR effect of the SHBG raising
allele, which, because raised SHBG levels are correlated
with reduced risk of type 2 diabetes, we expected to be
,1.0, if SHBG levels are involved in the aetiology of type
2 diabetes. Given the different levels of SHBG in men and
women we repeated analyses stratified by sex.
Observed differences in SHBG levels between type 2
diabetes patients and controls
SHBG levels are not routinely measured in type 2 diabetes
patients and controls. Instead, we used data from type 2
diabetes studies (four of men only and three of women only)
that had measured SHBG levels. These studies were men
and women from the InCHIANTI study (24) and the cross-
sectional studies published in the meta-analysis conducted
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by Ding et al. (1), for which we were able to retrieve mean and
standard deviation measures of SHBG in cases and controls,
were restricted to individuals of European ancestry, and had
matched or corrected SHBG levels for body mass index or
waist circumference. Details of these studies are given in
Table 2. For each study, we tabulated six variables: number
of cases, mean case SHBG levels, standard deviation of case
SHBG levels, number of controls, mean control SHBG
levels and standard deviation of control SHBG levels, using
ngmol21 as the units of SHBG. We performed an inverse var-
iance weighted meta-analysis of these studies, both overall and
within sexes, using the ‘metan’ command in STATAv10, to
derive a standardized mean difference (SMD) of SHBG
levels between type 2 diabetes cases and controls.
Approximation of the expected association between SHBG
SNP and type 2 diabetes risk
We used the estimates of the effect of rs1799941 on SHBG
levels in (i) and the correlation between SHBG levels and
type 2 diabetes estimated in (iii) to calculate an approximate
expected effect of rs1799941 on type 2 diabetes, assuming
that there is an aetiological association between SHBG
levels and type 2 diabetes risk. We used the formula:
ORexpected ¼ expð1:81 ðSDA  SMDBÞÞ
where SDA is the per allele effect of rs1799941 on circulating
SHBG levels expressed as a standard deviation and SMDB is
the standardized mean difference (SMD) of SHBG levels
between type 2 diabetes cases and controls. This approach
has previously been described in the context of diabetes-
related traits (29) and the rationale for the formula for appr-
oximating SMDs to ORs is described in more detail in
Chinn et al. (30). The figure 1.81 is the scaling factor used
to approximate ln(ORs) to and from standardized mean differ-
ences (30).
Associations between SHBG SNP and type 2 diabetes
related traits
To test for associations between the SHBG SNP rs1799941 (or
its close proxy rs12150660) and type 2 diabetes related traits,
Table 1. Characteristics of type 2 diabetes patients and controls from 15 studies
Study Type 2 diabeties Control
N Age BMI N Age BMI
Mean SD Mean SD Mean SD Mean SD
Men
WTCCC 1334 50.15 9.08 30.43 5.32 1042 N/A N/A N/A N/A
Dundee 2205 55.38 8.81 30.78 5.36 2283 59.98 11.41 27.16 3.95
EFS-Y2D 102 40 5.45 30.63 4.9 861 32.7 5.97 26.59 3.87
Danish 2049 56.55 8.87 30.24 4.88 2252 47.06 9.16 26.11 3.52
DGIa 742 N/A N/A N/A N/A 707 N/A N/A N/A N/A
Malmo¨ CC 1641 56.76 11 29.09 4.9 1287 57.7 6.08 25.52 3.08
FUSION1a,b 623 53.59 9.09 29.44 4.02 573 63.42 7.62 27.02 3.52
KORAb 669 60.4 9.1 29.7 4.7 840 60.5 9 28 3.9
Cambridgeshire CCb 346 63.4 7.9 28.7 3.8 343 63.7 7.9 27.1 3.5
ADDITION/ELYb 553 60.2 7.5 32.3 5.4 725 61.2 9.2 27.1 3.9
NDCCSb 3,575 66.4 10.6 29.3 4.8 3,038 58.9 9.1 26.3 3.1
DeCODE 832 55 12.1 29.7 4.9 7603 64.3 16.4 27.4 4.5
FUSION2 646 58.3 8.82 30.23 4.96 724 57.45 7.58 26.74 3.41
METSIMc 818 60.84 5.99 30.07 5.2 3372 57.98 6.4 26.25 3.46
DIAGEN 255 62.55 11.06 29.25 4.46 267 55.87 14.38 26.52 3.48
Total 16 390 25 917
Women
WTCCC 951 49.82 9.56 32.86 7.08 1039 N/A N/A N/A N/A
Dundee 1666 56.36 8.98 32.82 6.83 2414 56.97 12.04 26.89 5.17
EFS-YT2D 89 37.88 7.18 34.14 7.78 901 30.44 5.25 23.97 4.39
Danish 1398 57.35 9.89 31.28 6.28 2607 46.81 8.97 25.08 4.39
DGIa 722 N/A N/A N/A N/A 760 N/A N/A N/A N/A
Malmo¨ CC 1150 59.46 11.89 30.46 6.13 2210 57.34 5.96 24.79 3.83
FUSION1a,b 470 54.03 8.98 31.2 5.25 599 63.71 7.27 27.24 4.14
KORAb 538 61.6 9.4 31.8 5.8 678 61.4 9.2 27.9 4.7
Cambridgeshire CCb 202 63.3 7.9 31.6 6.8 191 63.5 7.7 27.8 5.1
ADDITION/ELYb 339 62.9 6.4 34.2 6 885 60.5 9.1 27.1 5.4
NDCCSb 2,481 67.1 11.4 30.8 6.5 3,390 57.8 9.3 25.9 4
DeCODE 582 55.2 12.7 30.6 6 16007 57.2 18.2 26.5 5.2
FUSION2 437 61.09 7.45 31.75 5.76 463 60.92 7.34 27.14 4.6
DIAGEN 242 67.49 12.3 31.09 7 420 55.93 14.09 26.62 4.78
Total 11 267 32 564
N/A, clinical characteristics not available separated by sex. Age is the age at diagnosis for diabetic patients unless otherwise stated.
aDGI and FUSION1 studies used proxy SNP (r2 ¼ 0.9) from GWAS data rs12150660.
bAge at recruitment given for these studies.
cMETSIM is a study of men only.
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we used data from a variety of sources. For measures of
fasting glucose and homeostatic model assessment (HOMA)
based measures of insulin resistance, we used data from
MAGIC of between 36 135 and 45 691 individuals, details
of which are described in detail elsewhere (31). For measures
of insulin secretion, we used 5771 individuals from the Danish
study, details of which are described in detail elsewhere (32).
For measures of whole body/peripheral insulin resistance, we
used 1229 individuals from the RISC study (33). All statistical
tests were performed using appropriate transformations
(described in the relevant publications) and a per allele 1.d.f.
test (in keeping with the additive effect of rs1799941 on
SHBG levels).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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